Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the Company entered into a global collaboration and exclusive ...

Halozyme Therapeutics Inc. has entered into a global collaboration and exclusive license agreement with Takeda.

− Topline Results for TAK-279 Show that a Significantly Greater Proportion of Psoriatic Arthritis Patients Achieved at Least an ACR20 Response Compared to Placebo at Week 12 1 − Based on the Positive ...

One way Takeda lives out its values is by striving to ensure that patients are aware of and can access the company’s clinical ...

Takeda and Protagonist Therapeutics have jointly submitted a new drug application (NDA) seeking approval from the US Food and ...

Takeda Pharmaceutical (NYSE:TAK) operates globally in healthcare, focusing on specialty medicines, biologics, and clinical ...

OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif., January 05, 2026--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist") announced the submission of a New Drug ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for ...

LONDON/NEW YORK/TOKYO (Reuters) - Rare disease specialist Shire (SHP.L) said on Wednesday it was willing to recommend a sweetened $64 billion (46 billion pounds) offer from Japan's Takeda ...

XOMA Royalty (XOMA) and Takeda (TAK) stock in focus as the companies ink a new royalty deal and armed an existing agreement.

Takeda Pharmaceutical Co. announced that its oral psoriasis drug zasocitinib proved safe and effective in late-stage trials, marking a milestone in its effort to treat the incurable skin condition and ...

We just closed out our fiscal year 2022 with a strong performance, at or above management guidance. Despite the global uncertainties, we have shown continued resilience and growth through innovation ...